Amgen (AMGN) has reported that its phase 3 DeLLphi-305 study yielded positive results, successfully achieving its primary endpoint with the use of IMDELLTRA alongside AstraZeneca's (AZN LN) Imfinzi.

08 Sep 2026 · 13:03 UTC

Observed price moves

AMGN-0.14%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next. We pay about $120,000 a month for the newswires behind this feed.